Evidence map›Paper›PMID 40696044›Full record

ArticleNature immunology2025

LARP4-mediated hypertranslation drives T cell dysfunction in tumors.

Yi Liu, Haochen Ni, Jie Li, Jing Yang, Ivann Sekielyk, Bryan E Snow, Zihao Zhang, Feifan Zhang, Michael St Paul, Jinyi Han and 9 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. ALDH1L1 reverses CD8Journal of translational medicine · 2026
    Article
  5. Article
  6. Review
  7. Translational Downregulation of 5' TOP mRNAs During T Cell Exhaustion.bioRxiv : the preprint server for biology · 2025
    Article
  8. Proteasome: Role in T Cell Function Regulation.International journal of biological sciences · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Yi Liu *Institute for Immunology, Tsinghua University, Beijing, China.
Haochen Ni *China National Center for Bioinformation, Beijing, China.
Jie Li *China National Center for Bioinformation, Beijing, China.ORCID http://orcid.org/0000-0002-4732-5967
Jing YangChina National Center for Bioinformation, Beijing, China.ORCID http://orcid.org/0000-0001-5199-7435
Ivann SekielykPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Bryan E SnowPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Zihao ZhangInstitute for Immunology, Tsinghua University, Beijing, China.
Feifan ZhangChina National Center for Bioinformation, Beijing, China.
Michael St PaulPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5213-6415
Jinyi HanInstitute for Immunology, Tsinghua University, Beijing, China.
Meghan KatesPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Shaofeng LiuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Yawei ZhangChina National Center for Bioinformation, Beijing, China.
Zurui HuangChina National Center for Bioinformation, Beijing, China.
Yin XuChina National Center for Bioinformation, Beijing, China.
Samuel D SaibilPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Tak W MakPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-6766-861X
Dali HanChina National Center for Bioinformation, Beijing, China. handl@big.ac.cn.ORCID http://orcid.org/0000-0001-7119-1578
Meng Michelle XuInstitute for Immunology, Tsinghua University, Beijing, China. michellexu@mail.tsinghua.edu.cn.ORCID http://orcid.org/0009-0007-1639-5640

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22293052National Natural Science Foundation of China (National Science Foundation of China) 32121001National Natural Science Foundation of China (National Science Foundation of China) 32370644
6 · The paper itself

Abstract

Adoptive T cell therapies have therapeutic potential for treating solid tumors, but long-term efficacy is limited by reduced functional fitness and poor persistence within the tumor microenvironment. Here we show that intratumoral T cells undergo translatome remodeling, transitioning into a hypertranslational state as they acquire dysfunctional traits. The RNA-binding protein LARP4 is a translation regulator that drives hypertranslation and dysfunction by selectively enhancing the translation of nuclear-encoded oxidative phosphorylation (OXPHOS) mRNAs in exhausted T cells, disrupting OXPHOS subunit balance and causing mitochondrial dysfunction. Knockout of Larp4 in tumor-specific CD8

Indexed as

AutoantigensCD8-Positive T-LymphocytesNeoplasmsRibonucleoproteinsAnimalsCell Line, TumorHumansImmunotherapy, AdoptiveMiceMice, Inbred C57BLMice, KnockoutMitochondriaOxidative PhosphorylationProtein BiosynthesisTumor MicroenvironmentAutoantigensRibonucleoproteins

Identifiers

PMID40696044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.